GLP-1 medications like semaglutide (Ozempic) and tirzepatide (Mounjaro) are transforming the landscape of weight loss, diabetes management, and metabolic health. In this episode of the Rare Wellness Podcast, Dr. Jamie Lewis breaks down the science behind GLP-1 receptor agonists—how they work, their benefits, and what happens when you stop taking them.

In this episode, you’ll learn:

✅ What GLP-1 receptor agonists are and how they function

✅ The key differences between semaglutide vs. tirzepatide

✅ How these medications promote fat loss, insulin sensitivity & metabolism

✅ The truth about weight regain after stopping GLP-1s

✅ Why long-term lifestyle changes are key for sustainable results

📌 Learn more about regenerative & performance medicine: www.nwc4rm.com

🔥 If you found this helpful, don’t forget to like, comment & subscribe for more expert insights on wellness, longevity, and metabolic health!

Works Cited:

1  Wilding, J. P., et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." The New England Journal of Medicine.

2  Jastreboff, A. M., et al. (2022). "Tirzepatide Once Weekly for the Treatment of Obesity." The New England Journal of Medicine.

3  Davies, M., et al. (2022). "Semaglutide 2.4 mg in Adults with Obesity or Overweight: Effects on Weight Loss and Maintenance." The Lancet.

4  Wadden, T. A., et al. (2022). "Weight Regain After Discontinuation of GLP-1 Receptor Agonists." Obesity Reviews.